Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Biography

  • Represented AEON Biopharma, Inc. as issuer's counsel in connection with its $13.75 million upsized offering of common stock, pre-funded warrants and milestone warrants
  • Represented Cyabra, Inc. as issuer's counsel in connection with a $6 million private placement of common stock and warrants
  • Represented Duke Robotics Corp. as issuer's counsel in connection with a $9.2 million underwritten public offering of shares and warrants, and concurrent uplisting to Nasdaq under the symbols “DUKR” and “DUKRW”
  • Represented A.G.P./Alliance Global Partners as placement agent's counsel in connection with a $22.5 million PIPE offering of common stock and pre-funded warrants by CNS Pharmaceuticals, Inc.
  • Represented A.G.P./Alliance Global Partners as financial advisor's counsel in connection with a $2.61 million private placement and warrant inducement transaction of American Depositary Shares (ADSs) by Scinai Immunotherapeutics Ltd.
  • Represented A.G.P./Alliance Global Partners as placement agent's counsel in connection with a $7.5 million public offering of common stock and warrants by Soligenix, Inc.
  • Represented A.G.P./Alliance Global Partners as placement agent's counsel in a $1.5 billion direct offering and concurrent PIPE offering of common stock (or equivalent) by AI Financial Corporation
  • Represented A.G.P./Alliance Global Partners and Societe Generale as placement agents' counsel in connection with a $200 million registered direct offering of common stock by SharpLink Gaming, Inc.
  • Represented Channel Therapeutics Corporation (now Pelthos Therapeutics Inc.) as legal counsel in connection with its $50 million private placement, completed in conjunction with the merger of a subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND) into Channel Therapeutics. Following the transaction, the combined company now operates under the name Pelthos Therapeutics Inc.

Matters

  • Represented AEON Biopharma, Inc. as issuer's counsel in connection with its $13.75 million upsized offering of common stock, pre-funded warrants and milestone warrants
  • Represented Cyabra, Inc. as issuer's counsel in connection with a $6 million private placement of common stock and warrants
  • Represented Duke Robotics Corp. as issuer's counsel in connection with a $9.2 million underwritten public offering of shares and warrants, and concurrent uplisting to Nasdaq under the symbols “DUKR” and “DUKRW”
  • Represented A.G.P./Alliance Global Partners as placement agent's counsel in connection with a $22.5 million PIPE offering of common stock and pre-funded warrants by CNS Pharmaceuticals, Inc.
  • Represented A.G.P./Alliance Global Partners as financial advisor's counsel in connection with a $2.61 million private placement and warrant inducement transaction of American Depositary Shares (ADSs) by Scinai Immunotherapeutics Ltd.
  • Represented A.G.P./Alliance Global Partners as placement agent's counsel in connection with a $7.5 million public offering of common stock and warrants by Soligenix, Inc.
  • Represented A.G.P./Alliance Global Partners as placement agent's counsel in a $1.5 billion direct offering and concurrent PIPE offering of common stock (or equivalent) by AI Financial Corporation
  • Represented A.G.P./Alliance Global Partners and Societe Generale as placement agents' counsel in connection with a $200 million registered direct offering of common stock by SharpLink Gaming, Inc.
  • Represented Channel Therapeutics Corporation (now Pelthos Therapeutics Inc.) as legal counsel in connection with its $50 million private placement, completed in conjunction with the merger of a subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND) into Channel Therapeutics. Following the transaction, the combined company now operates under the name Pelthos Therapeutics Inc.